National Health (Listed drugs on F1 or F2) Amendment Determination 2019 (No. 1) (PB 5 of 2019) (Cth)

PB 5 of 2019

National Health (Listed drugs on F1 or F2) Amendment Determination 2019 (No. 1)

National Health Act 1953

I, THEA DANIEL, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this determination under subsection 85AB(1) of the National Health Act 1953.

Dated       29 January 2019

THEA DANIEL

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

Part 1         Preliminary

1. Name of Determination

(1)   This Determination is the National Health (Listed drugs on F1 or F2) Amendment Determination 2019 (No. 1).

(2)   This Determination may also be cited as PB 5 of 2019.

1. Commencement

This Determination commences on 1 February 2019.

1. Amendment of National Health (Listed drugs on F1 or F2) Determination 2010

Schedule 1 amends the National Health (Listed drugs on F1 or F2) Determination 2010 (PB 93 of 2010).

Schedule 1             Amendments

(Section 3)

[1]     Schedule 1, after item dealing with Ferric carboxymaltose

Insert

Ferric derisomaltose

[2]     Schedule 1, after item dealing with Gefitinib

Omit

Gelatin-succinylated

[3]     Schedule 1, after item dealing with Guanfacine

Insert

Guselkumab

[4]     Schedule 1, after item dealing with Olsalazine

Insert

Osimertinib

[5]     Schedule 1, after item dealing with Ranibizumab

Omit

Rasagiline

[6]     Schedule 1, after item dealing with Ticagrelor

Insert

Tildrakizumab

[7]     Schedule 2, after item dealing with Ranitidine

Insert

Rasagiline